Provided by Tiger Trade Technology Pte. Ltd.

Sanofi SA

39.92
-0.7500-1.84%
Post-market: 40.180.2568+0.64%17:05 EDT
Volume:4.33M
Turnover:172.54M
Market Cap:95.65B
PE:21.41
High:40.07
Open:39.58
Low:39.50
Close:40.67
52wk High:52.68
52wk Low:39.50
Shares:2.40B
Float Shares:2.16B
Volume Ratio:1.18
T/O Rate:0.20%
Dividend:2.32
Dividend Rate:5.81%
EPS(TTM):1.86
EPS(LYR):3.76
ROE:5.71%
ROA:5.09%
PB:1.23
PE(LYR):10.62

Loading ...

MacroGenics to Receive $24.5 Million in Regulatory Milestone Payment

MT Newswires Live
·
Jun 23

European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading

MT Newswires Live
·
Jun 22

Movement Alert|Sanofi Falls 3.19% in Regular Trading, Phase III Trial Failure of Key Pipeline Drug Continues to Weigh on Shares

Market Focus
·
Jun 22

Sanofi Names New Pharma Research Head as CEO Moves to Speed Up Pipeline -- Update

Dow Jones
·
Jun 22

Movement Alert|Sanofi Falls 3.02% in Pre-Market Trading, Aftershocks From Core Pipeline Drug Phase III Trial Failure Continue

Market Focus
·
Jun 22

Movement Alert|Sanofi Falls 3.11% in Regular Trading, Continued Fallout from Core Pipeline Drug Phase III Trial Failure

Market Focus
·
Jun 18

European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading

MT Newswires Live
·
Jun 17

European Equities Traded in the US as American Depositary Receipts Surge in Monday Trading

MT Newswires Live
·
Jun 15

Sanofi Says US FDA Approved Tzield for Recently Diagnosed Stage 3 Type 1 Diabetes in Children

MT Newswires Live
·
Jun 15

Sanofi's Tzield Receives FDA Approval for Diabetes Treatment

Dow Jones
·
Jun 13

Buy Dianthus on weakness amid ‘overdone’ selloff, says H.C. Wainwright

TIPRANKS
·
Jun 10

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday Amid Renewed US-Iran Clashes

MT Newswires Live
·
Jun 10

Dianthus sinks after Sanofi halts CIDP Phase 3 study

TIPRANKS
·
Jun 10

Sanofi to halt riliprubart Mobilize phase 3 study

TIPRANKS
·
Jun 10

Sanofi's Development Pipeline Stumbles Again as Rare Disease Drug Trial Halts, Adding Pressure on New CEO

Stock News
·
Jun 10

Sanofi Stops Late-Stage Trial of Autoimmune Disease Therapy After Interim Review

MT Newswires Live
·
Jun 10

Sanofi to Stop Late-Stage Study of Immune-Disorder Drug

Dow Jones
·
Jun 10

European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading

MT Newswires Live
·
Jun 08

Sanofi's Subcutaneous Sarclisa Approved in EU Across Multiple Myeloma Indications

MT Newswires Live
·
Jun 08

Movement Alert|Sanofi Rises 4.59% in Regular Trading, First-in-Class Drug Venglustat Granted FDA Priority Review for Rare Disease

Market Focus
·
Jun 04